This conference covers recent advances in the discovery and development of new drugs for the treatment of chronic neurodegenerative disease.
Chronic age related neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease represent a huge and increasing disease burden to society. By 2013 the incidence rate for Alzheimer's disease is forecast to be 0.98% representing 7.4 million newly diagnosed patients per year.
By mid-century, estimates suggest that there will be more than 100 million patients worldwide. The drugs available for Alzheimer's disease only treat the cognitive symptoms and the level of efficacy obtained is not regarded by some authorities as providing cost effective therapy. New treatments for disease progression and more effective symptomatic therapies are urgently required. The challenge involved in the discovery and development of novel drug targets for the treatment of neurodegenerative diseases is a major task for both the academic and pharmaceutical communities. This area represents the most important unmet medical need in the treatment of CNS disease.
The programme covers translational approaches to drug discovery and presents drug discovery strategies for symptomatic therapy and the reduction of disease progression.
Chronic age related neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease represent a huge and increasing disease burden to society. By 2013 the incidence rate for Alzheimer's disease is forecast to be 0.98% representing 7.4 million newly diagnosed patients per year.
By mid-century, estimates suggest that there will be more than 100 million patients worldwide. The drugs available for Alzheimer's disease only treat the cognitive symptoms and the level of efficacy obtained is not regarded by some authorities as providing cost effective therapy. New treatments for disease progression and more effective symptomatic therapies are urgently required. The challenge involved in the discovery and development of novel drug targets for the treatment of neurodegenerative diseases is a major task for both the academic and pharmaceutical communities. This area represents the most important unmet medical need in the treatment of CNS disease.
The programme covers translational approaches to drug discovery and presents drug discovery strategies for symptomatic therapy and the reduction of disease progression.
